Drug
FB2001
FB2001 is a pharmaceutical drug with 5 clinical trials. Historical success rate of 100.0%.
Total Trials
5
Max Phase
—
Type
DRUG
Molecule
—
Success Metrics
Clinical Success Rate
100.0%
Based on 2 completed trials
Completion Rate
100%(2/2)
Active Trials
0(0%)
Results Posted
0%(0 trials)
Phase Distribution
Ph phase_2
2
40%
Ph phase_1
3
60%
Phase Distribution
3
Early Stage
2
Mid Stage
0
Late Stage
Phase Distribution5 total trials
Phase 1Safety & dosage
3(60.0%)
Phase 2Efficacy & side effects
2(40.0%)
Highest Phase Reached
Phase 2Trial Status & Enrollment
Completion Rate
100.0%
2 of 2 finished
Non-Completion Rate
0.0%
0 ended early
Currently Active
0
trials recruiting
Total Trials
5
all time
Status Distribution
Completed(2)
Other(3)
Detailed Status
unknown3
Completed2
Development Timeline
Analytics
Development Status
Total Trials
5
Active
0
Success Rate
100.0%
Most Advanced
Phase 2
Trials by Phase
Phase 13 (60.0%)
Phase 22 (40.0%)
Trials by Status
completed240%
unknown360%
Recent Activity
0 active trials
Showing 5 of 5
unknownphase_2
Evaluate the Efficacy and Safety of FB2001 for Inhalation in Patients With Mild to Moderate COVID-19
NCT05675072
unknownphase_2
Evaluate the Efficacy and Safety of FB2001 in Hospitalized Patients With Moderate to Severe COVID-19 (BRIGHT Study)
NCT05445934
completedphase_1
The Safety and Efficacy of FB2001 in Healthy Subjects and Patients With COVID-19 Infection
NCT04766931
completedphase_1
A Bridging Study of FB2001 in Healthy Subjects
NCT05197179
unknownphase_1
Exploratory Study of Aerosol Inhalation of FB2001 for Post-exposure Prophylaxis of COVID-19 Close Contacts
NCT05415241
Clinical Trials (5)
Showing 5 of 5 trials
NCT05675072Phase 2
Evaluate the Efficacy and Safety of FB2001 for Inhalation in Patients With Mild to Moderate COVID-19
NCT05445934Phase 2
Evaluate the Efficacy and Safety of FB2001 in Hospitalized Patients With Moderate to Severe COVID-19 (BRIGHT Study)
NCT04766931Phase 1
The Safety and Efficacy of FB2001 in Healthy Subjects and Patients With COVID-19 Infection
NCT05197179Phase 1
A Bridging Study of FB2001 in Healthy Subjects
NCT05415241Phase 1
Exploratory Study of Aerosol Inhalation of FB2001 for Post-exposure Prophylaxis of COVID-19 Close Contacts
All 5 trials loaded
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 5